Panel recommends Lilly continue breast cancer drug study

August 10, 2016 11:06 AM

21 0

Panel recommends Lilly continue breast cancer drug study

Eli Lilly and Co said an interim analysis of a late-stage study testing its breast cancer drug abemaciclib by an independent panel showed the treatment did not meet the effectiveness criteria and recommended that the company continue the trial.

The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer.

Also read: Jury In S.C. Police Shooting Trial Says It Is Struggling To Reach Verdict

Read more

To category page

Loading...